Literature DB >> 9061749

Haemoglobinopathies.

J Old1.   

Abstract

The inherited haemoglobinopathies are a heterogeneous group of recessive disorders that include the thalassaemias and sickle cell disease. Nearly a thousand mutant alleles have now been characterized. The mutations are regionally specific and in most cases the geographical and ethnic distributions have been determined providing the foundation for a programme of control through screening, genetic counselling and prenatal diagnosis. The main requirements for methodologies providing molecular diagnosis are speed, cost, convenience and the ability to test for multiple mutations simultaneously. For beta-thalassaemia mutations the procedures that meet these requirements are the amplification refractory mutation system and the reverse dot-blot hybridization system. For alpha-thalassaemia the technique of gap PCR is useful for targeting specific deletion mutations but Southern blotting remains the standard diagnostic test.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9061749     DOI: 10.1002/(SICI)1097-0223(199612)16:13<1181::AID-PD93>3.0.CO;2-N

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  4 in total

Review 1.  Automated mutation analysis.

Authors:  D Ravine
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Comparison of capillary electrophoresis with cellulose acetate electrophoresis for the screening of hemoglobinopathies.

Authors:  Ji-Eun Kim; Bo-Ram Kim; Kwang-Sook Woo; Jeong-Man Kim; Joo-In Park; Jin-Yeong Han
Journal:  Korean J Lab Med       Date:  2011-10-03

3.  Prevalence and Genetic Analysis of α- and β-Thalassemia and Sickle Cell Anemia in Southwest Iran.

Authors:  Forozan H Nezhad; Khojasteh H Nezhad; Parastoo M Choghakabodi; Bijan Keikhaei
Journal:  J Epidemiol Glob Health       Date:  2018-12

4.  Co-inheritance of sickle cell trait and thalassemia mutations in South central iran.

Authors:  N Saleh-Gohari; M Mohammadi-Anaie
Journal:  Iran J Public Health       Date:  2012-10-01       Impact factor: 1.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.